arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CytomX Therapeutics, Inc.

CTMX
$2.12 ▼ -0.23 (-10.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

CytomX Therapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $464.2M
Dividend Yield —
Revenue Growth -92.4% ↘
Op. Margin None
ROIC -7.9% ↘
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.42M
↓ -92.4% —
Net Income Profit after all expenses
$-18.25M
— 0.0% —
Operating Margin Operating profit as % of sales
-191.8%
↑ +27.5% 8th
FCF / Share Free cash flow per share
$-0.08
↑ +42.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
7
Returns ↑
29
Cash Quality ↑
94

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 51 quarters